Study: 60 Percent of Tuberous Sclerosis Complex Patients Who Used CBD
Products Saw Significant Reduction of Seizures
A new study has found promising results in
CBD oil used as a treatment for patients
suffering from seizures—primarily people
with Tuberous Sclerosis Complex.
Results from the trial showed that 60 percent
of participants who used CBD products saw a
clinically significant (80-100 percent)
reduction in the frequency of their seizures.
The recent clinical study was conducted by
renowned Mexico neurologist, Dr. Carlos G.
Aguirre-Velazquez.
Mexico’s advancements in medical cannabis
made international headlines this summer
after the State of Mexico announced it would
provide cannabidiol (CBD) oil to citizens.
Dr. Stuart Titus, CEO of Medical Marijuana,
Inc. said “We applaud Dr. Aguirre for his
work in unveiling, like he did in this study,
that not only is CBD effective in relieving
seizures, but also exhibiting that CBD can be
used over long periods of time without harm,
compared to antiepileptic or broad-spectrum
steroids that can have dangerous side effects
if used for several years, including vision and
damage to major organs.”
Patients with varying forms of epilepsy
participated in the trial, with the majority
having TSC, a genetic disorder characterised
by the growth of noncancerous (benign
tumours) in many parts of the body, including
the brain, which can lead to convulsive crises.
TSC affects 1 million people worldwide,
50,000 in the U.S. and 20,000 in Mexico.
Research targeted the reduction in frequency,
intensity and duration of convulsive crises in
people with tuberous sclerosis complex.
Other factors observed in the study were
quality of life, dependence on heavy
prescription
drugs
and
long-term
sustainability of treatment with CBD.
Additionally, quality of life metrics such as
mood, appetite and cognition saw substantial
increases among the patients using CBD.
Finally, no serious side effects were reported,
only mild ones such as drowsiness and
increase in appetite, which eventually
disappeared with the need to reduce the dose.